| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Pediatrics (Drs. Eirís, Novo, Bravo, Pavón, and Castro-Gago), Division of Pediatric Neurology, and the Central Laboratory Service (Drs. Lojo and Del Río), Hospital General de Galicia, Clínico Universitario, Santiago de Compostela, Spain.
Article abstract—We determined serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and triglycerides (TGs) in 125 healthy children and in 119 children with epilepsy who had been receiving carbamazepine (58 children), pheno-barbital (22 children), or valproic acid (39 children) for 7 months to 10.5 years (mean, 5.8 years). None of the variables considered was significantly correlated with time elapsed since start of treatment or with drug concentration in serum. In the groups receiving carbamazepine or phenobarbital, mean TC, HDL-C, and LDL-C levels were higher than in the control group, the differences being statistically significant for all except LDL-C in the phenobarbital group. In neither group did mean TC/HDL-C ratio or mean LDL-C/HDL-C ratio differ significantly from the corresponding control-group mean. In the group receiving valproic acid, mean TC level, mean LDL-C level, mean TC/HDL-C ratio, and mean LDL-C/HDL-C ratio were significantly lower than in the control group. In none of the treated groups did mean VLDL-C or TG level differ significantly from the corresponding control-group mean. Our results suggest, in contrast to previous reports, that the effects on the serum lipid profile of long-term treatment with hepatic-enzyme—inducing antiepileptic drugs (such as carbamazepine and phenobarbital) are probably not beneficial as regards risk of atherosclerosis-related disease. Our results additionally suggest a need for careful monitoring of serum cholesterol levels in children with epilepsy receiving carbamazepine or phenobarbital.
This article has been cited by other articles:
|
|
 |
|
  C. Zhou, N. King, K. Y. Chen, and J. L. Breslow Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice J. Lipid Res., October 1, 2009; 50(10): 2004 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Tomoum, M. M. Awadallah, D. A. Fouad, and A. H. Ali Lipid Profile, Apolipoproteins A and B in Children With Epilepsy J Child Neurol, November 1, 2008; 23(11): 1275 - 1281. [Abstract] [PDF]
|
|
|
|
|
|
M. Castro-Gago, M. I. Novo-Rodriguez, M. O. Blanco-Barca, A. Urisarri-Ruiz de Cortazar, J. Rodriguez-Garcia, S. Rodriguez-Segade, and J. Eiris-Punal Evolution of Serum Lipids and Lipoprotein (a) Levels in Epileptic Children Treated With Carbamazepine, Valproic Acid, and Phenobarbital J Child Neurol, January 1, 2006; 21(1): 48 - 53. [Abstract] [PDF]
|
|
|
|
|
|
F. Mujgan Sonmez, E. Demir, A. Orem, S. Yildirmis, F. Orhan, A. Aslan, and M. Topbas Effect of Antiepileptic Drugs on Plasma Lipids, Lipoprotein (a), and Liver Enzymes J Child Neurol, January 1, 2006; 21(1): 70 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 X.-N. Li, Q. Shu, J. M.-F. Su, L. Perlaky, S. M. Blaney, and C. C. Lau Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC Mol. Cancer Ther., December 1, 2005; 4(12): 1912 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gnerre, G. U. Schuster, A. Roth, C. Handschin, L. Johansson, R. Looser, P. Parini, M. Podvinec, K. Robertsson, J.-A. Gustafsson, et al. LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver J. Lipid Res., August 1, 2005; 46(8): 1633 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Luef and W. Poewe Oxcarbazepine in glossopharyngeal neuralgia: Clinical response and effect on serum lipids Neurology, December 28, 2004; 63(12): 2447 - 2448. [Full Text] [PDF]
|
|
|
|
|
|
R. Sankar Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues Neurology, November 23, 2004; 63(10_suppl_4): S30 - S39. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. J. Tutor-Crespo, J. Hermida, and J. C. Tutor Possible Induction of Cholinesterase in Epileptic Patients Treated With Anticonvulsant Drugs: Relationship With Lipoprotein Levels J. Clin. Pharmacol., September 1, 2004; 44(9): 974 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. de Chadarevian, A. Legido, D. K. Miles, and C. D. Katsetos Epilepsy, Atherosclerosis, Myocardial Infarction, and Carbamazepine J Child Neurol, February 1, 2003; 18(2): 150 - 151. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Handschin, M. Podvinec, R. Amherd, R. Looser, J.-C. Ourlin, and U. A. Meyer Cholesterol and Bile Acids Regulate Xenosensor Signaling in Drug-mediated Induction of Cytochromes P450 J. Biol. Chem., August 9, 2002; 277(33): 29561 - 29567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bramswig, A. Kerksiek, T. Sudhop, C. Luers, K. Von Bergmann, and H. K. Berthold Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H704 - H716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ueda, H. K. Hamadeh, H. K. Webb, Y. Yamamoto, T. Sueyoshi, C. A. Afshari, J. M. Lehmann, and M. Negishi Diverse Roles of the Nuclear Orphan Receptor CAR in Regulating Hepatic Genes in Response to Phenobarbital Mol. Pharmacol., January 1, 2002; 61(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mujgan Aynaci, F. Orhan, A. Orem, S. Yildirmis, and Y. Gedik Effect of Antiepileptic Drugs on Plasma Lipoprotein (a) and Other Lipid Levels in Childhood J Child Neurol, May 1, 2001; 16(5): 367 - 369. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Brewer and G. A. Colditz Postmarketing Surveillance and Adverse Drug Reactions: Current Perspectives and Future Needs JAMA, March 3, 1999; 281(9): 824 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Some Antiepileptic Drugs Raise Serum Lipids Journal Watch Psychiatry, August 1, 1995; 1995(801): 10 - 10. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
